{
  "pmid": "26633262",
  "topic": "steroid_sensitivity",
  "pdf_path": "Annane_Sepsis_Corpus\\papers\\PMID_26633262\\paper.pdf",
  "sectionizer": "simple_pdfplumber",
  "sections": {
    "Abstract": "CochraneDatabaseofSystematicReviews Corticosteroids for treating sepsis (Review) AnnaneD,BellissantE,BollaertPE,BriegelJ,KehD,KupferY AnnaneD,BellissantE,BollaertPE,BriegelJ,KehD,KupferY. Corticosteroidsfortreatingsepsis. CochraneDatabaseofSystematicReviews2015,Issue12.Art.No.:CD002243. DOI:10.1002/14651858.CD002243.pub3. www.cochranelibrary.com Corticosteroidsfortreatingsepsis(Review) Copyright©2018TheCochraneCollaboration.PublishedbyJohnWiley&Sons,Ltd. TABLE OF CONTENTS HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 PLAINLANGUAGESUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 SUMMARYOFFINDINGSFORTHEMAINCOMPARISON . . . . . . . . . . . . . . . . . . . 4 BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8",
    "Method": "METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8",
    "Conclusion": "RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Figure1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 Figure2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Figure3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 Figure4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 Figure5. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Figure6. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 AUTHORS’CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24 ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 CHARACTERISTICSOFSTUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31 DATAANDANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71 Analysis1.1.Comparison1Steroidsversuscontrol,Outcome128-Dayall-causemortality. . . . . . . . . . 73 Analysis1.2.Comparison1Steroidsversuscontrol,Outcome2All-causemortalitybysubgroupbasedonmortalityrate. 74 Analysis1.3.Comparison 1Steroidsversuscontrol,Outcome328-Dayall-causemortalitybysubgroups basedon methodologicalquality. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76 Analysis1.4.Comparison 1Steroidsversuscontrol,Outcome428-Dayall-causemortalitybysubgroups basedon treatmentdose/duration. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79 Analysis1.5.Comparison1Steroidsversuscontrol,Outcome528-Dayall-causemortalitybysubgroupsbasedontargeted population. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81 Analysis1.6.Comparison1Steroidsversuscontrol,Outcome628-Daymortalityinparticipantswithcriticalillness-related corticosteroidinsufficiency. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83 Analysis1.7.Comparison1Steroidsversuscontrol,Outcome7Intensivecareunitmortality. . . . . . . . . 84 Analysis1.8.Comparison1Steroidsversuscontrol,Outcome8Hospitalmortality. . . . . . . . . . . . . 85 Analysis1.9.Comparison1Steroidsversuscontrol,Outcome9Numberofparticipantswithshockreversalatday7. 86 Analysis1.10.Comparison1Steroidsversuscontrol,Outcome10Numberofparticipantswithshockreversalat28days. 88 Analysis1.11.Comparison1Steroidsversuscontrol,Outcome11SOFAscoreatday7. . . . . . . . . . . 89 Analysis1.12.Comparison1Steroidsversuscontrol,Outcome12LengthofICUstayforallparticipants. . . . . 90 Analysis1.13.Comparison1Steroidsversuscontrol,Outcome13LengthofICUstayforsurvivors. . . . . . . 91 Analysis1.14.Comparison1Steroidsversuscontrol,Outcome14Lengthofhospitalstayforallparticipants. . . . 92 Analysis1.15.Comparison1Steroidsversuscontrol,Outcome15Lengthofhospitalstayforsurvivors. . . . . . 93 Analysis1.16.Comparison1Steroidsversuscontrol,Outcome16Numberofparticipantswithadverseevents. . . 94 APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96 FEEDBACK . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100 WHAT’SNEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102 HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102 CONTRIBUTIONSOFAUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105 DECLARATIONSOFINTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105 SOURCESOFSUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106 NOTES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106 INDEXTERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107 Corticosteroidsfortreatingsepsis(Review) i Copyright©2018TheCochraneCollaboration.PublishedbyJohnWiley&Sons,Ltd. [InterventionReview] Corticosteroids for treating sepsis DjillaliAnnane1,EricBellissant2,PierreEdouardBollaert3,JosefBriegel4,DidierKeh5,YizhakKupfer6 1Department of Critical Care, Hyperbaric Medicine and Home Respiratory Unit, Center for Neuromuscular Diseases; Raymond PoincaréHospital(AP-HP),Garches,France.2Centred’InvestigationCliniqueINSERM0203,HôpitalPontchaillou,Rennes,France. 3Intensive CareUnit,HôpitalCentral,Nancy,France.4KlinikfurAnästhesiologie,KlinikumderUniversität, München,Germany. 5University Clinic of Anesthesiology and Intensive Care Medicine CCM/CVK, Charité-Campus Virchow Clinic, Charité Univer- sitätsmedizinBerlin,Berlin,Germany.6DivisionofPulmonaryandCriticalCareMedicine,MaimonidesMedicalCenter,Brooklyn, NewYork,USA Contactaddress:DjillaliAnnane,DepartmentofCriticalCare,HyperbaricMedicineandHomeRespiratoryUnit,CenterforNeu- romuscular Diseases; Raymond Poincaré Hospital (AP-HP), Faculty of HealthSciencesSimone Veil,University of VersaillesSQY- UniversityofParisSaclay,104BoulevardRaymondPoincaré,Garches,92380,France.djillali.annane@aphp.fr. Editorialgroup:CochraneEmergencyandCriticalCareGroup. Publicationstatusanddate:Edited(nochangetoconclusions),publishedinIssue12,2018. Citation: AnnaneD,BellissantE,BollaertPE,BriegelJ,KehD,KupferY.Corticosteroidsfortreatingsepsis.CochraneDatabaseof SystematicReviews2015,Issue12.Art.No.:CD002243.DOI:10.1002/14651858.CD002243.pub3. Copyright©2018TheCochraneCollaboration.PublishedbyJohnWiley&Sons,Ltd. ABSTRACT Background Sepsisoccurswhenaninfectioniscomplicatedbyorganfailuresasdefinedbyasequentialorganfailureassessment(SOFA)scoreoftwo orhigher.Sepsismaybecomplicatedbyimpairedcorticosteroidmetabolism.Givingcorticosteroidsmaybenefitpatients.Theoriginal reviewwaspublishedin2004andwasupdatedin2010andagainin2015. Objectives Toexaminetheeffectsofcorticosteroidsondeathatonemonthinpatientswithsepsis,andtoexaminewhetherdoseanddurationof corticosteroidsinfluencepatientresponsetothistreatment. Searchmethods WesearchedtheCentralRegisterofControlledTrials(CENTRAL;2014,Issue10),MEDLINE(October2014),EMBASE(October 2014),LatinAmericanCaribbeanHealthSciencesLiterature(LILACS;October2014)andreferencelistsofarticles,andwecontacted trialauthors.TheoriginalsearcheswereperformedinAugust2003andinOctober2009. Selectioncriteria Weincludedrandomizedcontrolledtrialsofcorticosteroidsversusplaceboorsupportivetreatmentinpatientswithsepsis. Datacollectionandanalysis Allreviewauthorsagreedontheeligibilityoftrials.Onereviewauthorextracteddata,whichwerecheckedbytheotherreviewauthors, andbytheprimaryauthorofthepaperwhenpossible.Weobtainedsomemissingdatafromtrialauthors.Weassessedthemethodological qualityoftrials. Corticosteroidsfortreatingsepsis(Review) 1 Copyright©2018TheCochraneCollaboration.PublishedbyJohnWiley&Sons,Ltd. Mainresults Weidentifiednineadditionalstudiessincethelastupdate,foratotalof33eligibletrials(n=4268participants).Twenty-threeofthese 33trialswereatlowriskofselectionbias,22wereatlowriskofperformanceanddetectionbias,27wereatlowriskofattritionbias and14wereatlowriskofselectivereporting. Corticosteroidsreduced28-daymortality(27trials;n=3176;riskratio(RR)0.87,95%confidenceinterval(CI)0.76to1.00;Pvalue =0.05,random-effectsmodel).Thequalityofevidenceforthisoutcomewasdowngradedfromhightolowforimprecision(upper limitof95%CI=1)andforinconsistency(significantheterogeneityacrosstrialresults).Heterogeneitywasrelatedinparttothedosing strategy.Treatmentwithalongcourseoflow-dosecorticosteroidssignificantlyreduced28-daymortality(22trials;RR0.87,95%CI 0.78to0.97;Pvalue=0.01,fixed-effectmodel).Thequalityofevidencewasdowngradedfromhightomoderateforinconsistency (owingtonon-significanteffectsshownbyonelargetrial).Corticosteroidsalsoreducedmortalityrateintheintensivecareunit(13 trials;RR0.82,95%CI0.68to1.00;Pvalue=0.04,random-effectsmodel)andatthehospital(17trials;RR0.85,95%CI0.73to 0.98;Pvalue=0.03,random-effectsmodel).Qualityoftheevidenceforin-hospitalmortalitywasdowngradedfromhightomoderate forinconsistencyandimprecision(upperlimitof95%CIforRRapproaching1).Corticosteroidsincreasedtheproportionofshock reversalbydayseven(12trials;RR1.31,95%CI1.14to1.51;Pvalue=0.0001)andbyday28(seventrials;n=1013;RR1.11,95% CI1.02to1.21;Pvalue=0.01)andreducedtheSOFAscorebydayseven(eighttrials;meandifference(MD)-1.53,95%CI-2.04 to-1.03;Pvalue<0.00001,random-effectsmodel)andsurvivors’lengthofstayintheintensivecareunit(10trials;MD-2.19,95% CI-3.93to-0.46;Pvalue=0.01,fixed-effectmodel)withoutinducinggastroduodenalbleeding(19trials;RR1.24,95%CI0.92to 1.67;Pvalue=0.15,fixed-effectmodel),superinfection(19trials;RR1.02,95%CI0.87to1.20;Pvalue=0.81,fixed-effectmodel) orneuromuscularweakness(threetrials;RR0.62,95%CI0.21to1.88;Pvalue=0.40,fixed-effectmodel).Corticosteroidincreased theriskofhyperglycaemia(13trials;RR1.26,95%CI1.16to1.37;Pvalue<0.00001,fixed-effectmodel)andhypernatraemia(three trials;RR1.64,95%CI1.28to2.09;Pvalue<0.0001,fixed-effectmodel). Authors’conclusions Overall,low-quality evidenceindicates thatcorticosteroids reducemortalityamong patientswithsepsis.Moderate-quality evidence suggeststhatalongcourseoflow-dosecorticosteroidsreduced28-daymortalitywithoutinducingmajorcomplicationsandledtoan increaseinmetabolicdisorders. PLAIN LANGUAGE SUMMARY Corticosteroidsfortreatingsepsis Reviewquestion Wereviewedtheevidenceoneffectsonsurvivalatonemonthandontoleranceofsystemiccorticosteroidsinpeoplewithsepsis. Background Sepsis,themostsevereformofinfection, ispresentwhenasiteofinfectionisapparentandevidencesuggestsbody-wide, systemic inflammationandorganfailures.Thepersondevelopspoortemperaturecontrol,anincreaseordecreaseinwhitebloodcells,anincrease inheartrateandrapidbreathing.Sepsiscaninterferewitheffectivenessofthebody’sowncorticosteroids,whichserveaskeydefence hormonesagainst infection. Corticosteroids havebeengivenfor more than60yearstopeoplewith severeinfection resultingfrom variouscauses. Searchdate TheevidenceprovidedinthisreviewwascurrenttoOctober2014. Studycharacteristics Thisreview included atotal of 33 randomized controlledtrials, accounting for 4268 hospitalizedpatients with sepsis. Three trials includedchildren,andtheremaining30trialsincludedonlyadults.Corticosteroidswerecomparedwithplaceboinallexceptfivetrials, inwhichtheywerecomparedwithstandardtherapyalone. Studyfundingsources Corticosteroidsfortreatingsepsis(Review) 2 Copyright©2018TheCochraneCollaboration.PublishedbyJohnWiley&Sons,Ltd. Tenoutof33trialswerefundedbyadrugcompany,13werefundedbypublicorganizationsorreceivedcharitablefundingand10 statednosourceoffunding. Keyresults Corticosteroidsreducedriskofdeathat28daysby13%(among27trials,3176participants).Bothintensivecareunit(ICU)andin- hospitaldeathswerereduced(13and17trials,respectively).Thereviewfoundthatsurvivalbenefitsweredependentonthedoseof corticosteroids-thelowerthedose(lessthan400mgofhydrocortisoneorequivalentperday)foralongerdurationoftreatment(three ormoredaysatthefulldose)thebetter-andontheseverityofillness.Corticosteroidsincreasedthechanceofrecoveryfromseptic shockbydayseven(whendrugsarerequiredtosupportbloodpressure)by31%(from12trials)andanddecreasedthenumberof organsthatwerenotfunctioningproperly(organfailure)(fromeighttrials).LengthofstayintheICUwasreducedbymorethantwo days(10trials).Corticosteroidsdidnotcauseharm,exceptforamildincreaseinbloodglucoseandsalt(sodium)levels(13andthree trials,respectively).Gastrointestinalbleedingandinfection(19trials)andneuromuscularweakness(threetrials)werenotincreased. Wefoundsparsedataoneffectsofcorticosteroidsinchildrenwithsepsis. Qualityofevidence Wejudgedthequalityofevidencefor28-daymortalityaslowbecauseofimprecision(theconfidenceintervalofthestatisticalresult approachednochange)andinconsistency acrosstrials.Thesefindingswererelatedinparttodifferencesamongstudypopulations, typeofcorticosteroidgiven,doseanddurationoftreatmentanduseofadditionalinterventions.Thequalityofevidencefor28-day mortalityinthesubgroupgivenalongcourseoflow-dosecorticosteroidswasdowngradedfromhightomoderatebecauseoneofthe twolargesttrialsonalongcourseoflow-dosecorticosteroidsreportednosurvivalbenefit. Corticosteroidsfortreatingsepsis(Review) 3 Copyright©2018TheCochraneCollaboration.PublishedbyJohnWiley&Sons,Ltd. SUMMARY OF FINDINGS FOR THE MAIN COMPARISON [Explanation] Steroidsversuscontrolfortreatingsepsis Patientorpopulation:patientswithsepsis Settings: Intervention:steroidsvscontrol Outcomes Illustrativecomparativerisks* (95%CI) Relativeeffect Numberofparticipants Qualityoftheevidence Comments (95%CI) (studies) (GRADE) Assumedrisk Correspondingrisk Control Steroidsvscontrol 28-Day all-cause mor- Studypopulation RR0.87 3176 ⊕⊕(cid:13)(cid:13) Trials were conducted tality (0.76to1) (27studies) Lowa,b overaperiodfrom1976 Follow-up: 14 to 30 to 2015. Differences days in participant manage- ment and in the defini- 318per1000 276per1000 tionofsepsisweresub- (241to318) stantial<BR/>18trial 28-Day all-cause mor- Studypopulation RR0.87 2266 ⊕⊕⊕(cid:13) Meta-regression analy- tality by subgroups (0.78to0.97) (22studies) Moderatea sis also showed evi- based on treatment dence of a dose re- dose/duration - long sponse: Low doses course of low-dose were associated with corticosteroids better treatment re- Follow-up: 14 to 30 321per1000 279per1000 sponse days (250to311) Hospitalmortality Studypopulation RR0.85 2014 ⊕⊕⊕(cid:13) Low doses of corti- Follow-up: 14 to 365 (0.73to0.98) (17studies) Moderatea,c costeroids were asso- days ciatedwithbettertreat- mentresponse Copyright©2018TheCochraneCollaboration.PublishedbyJohnWiley&Sons,Ltd. Corticosteroidsfortreatingsepsis(Review) 4 413per1000 351per1000 (302to405) Numberofparticipants Studypopulation RR1.31 1561 ⊕⊕⊕⊕ Low doses of corti- with shock reversal at (1.14to1.51) (12studies) High costeroids were asso- day7 523per1000 685per1000 ciatedwithbettertreat- Follow-up:7to28days (596to790) mentresponse SOFAscoreatday7 Mean SOFA score at 1132 ⊕⊕⊕⊕ Observed reduction in Follow-up:7days day 7 in intervention (8studies) High SOFA score was of groupswas a magnitude that ex- 1.53lower ceeded any reduction (2.04to1.03lower) seen with any other treatmentforsepsis Length of ICU stay for MeanlengthofICUstay 778 ⊕⊕⊕⊕ Observed reduction in survivors for survivors in inter- (10studies) High length of ICUstay was Follow-up: 14 to 365 ventiongroupswas of amagnitudethat ex- days 2.19lower ceeded any reduction (3.93to0.46lower) seen with any other treatmentforsepsis Lengthofhospitalstay Meanlengthofhospital 710 ⊕⊕⊕(cid:13) Observed reduction in forsurvivors stayfor survivors in in- (9studies) Moderatec length of hospital stay Follow-up: 14 to 365 terventiongroupswas was of a magnitude days 4.11lower that exceeded any re- (8.5 lower to 0.28 duction seen with any higher) othertreatmentforsep- sis Numberofparticipants Studypopulation RR1.02 2567 ⊕⊕⊕⊕ One large trial sug- with adverse events - (0.87to1.2) (19studies) High gestedincreasedriskof superinfections new sepsis with corti- Follow-up: 14 to 90 costeroids days Copyright©2018TheCochraneCollaboration.PublishedbyJohnWiley&Sons,Ltd. Corticosteroidsfortreatingsepsis(Review) 5 161per1000 164per1000 (140to193) Numberofparticipants Studypopulation RR1.26 2081 ⊕⊕⊕⊕ Onetrialsuggestedthat with adverse events - (1.16to1.37) (13studies) High risk of hyperglycaemia hyperglycaemia was lower when corti- Follow-up: 14 to 90 costeroids were given days as a continuous per- fusion than when they 348per1000 438per1000 were given as an intra- (403to476) venousbolus *Thebasisfortheassumedriskisprovidedinfootnotes.Thecorrespondingrisk(andits95%confidenceinterval)isbasedontheassumedriskinthecomparisongroupand therelativeeffectof theintervention(andits95%CI) CI:Confidenceinterval;RR:Riskratio GRADEWorkingGroupgradesof evidence Highquality:Furtherresearchisveryunlikelytochangeourconfidenceintheestimateof effect Moderatequality:Furtherresearchislikelytohaveanimportantimpactonourconfidenceintheestimateof effectandmaychangetheestimate Lowquality:Furtherresearchisverylikelytohaveanimportantimpactonourconfidenceintheestimateof effectandislikelytochangetheestimate Verylowquality:Weareveryuncertainabouttheestimate aQuality of evidencewas downgraded by 1 point owing to some inconsistency;1 of the 2 largest trials showed no survival benefit bQualityofevidencewasdowngradedby1pointowingtopotentialpublicationbias;someasymmetrywasnotedinthefunnel plot cQualityof evidencewasdowngradedby1pointforimprecision,andtheupperlimitof theconfidenceintervalapproached1 Copyright©2018TheCochraneCollaboration.PublishedbyJohnWiley&Sons,Ltd. Corticosteroidsfortreatingsepsis(Review) 6 BACKGROUND themonomericglucocorticoid-glucocorticoidreceptor(G-GR)α complexandvariousnucleartranscriptionfactors,suchasnuclear factor(NF)-κBandactivatorprotein(AP)-1.Subsequently,these nuclear transcription factors are sequestrated in the cytosol and Descriptionofthecondition cannotenterthenucleus,preventingexpressionofgenesencoding Sepsis occurs when a site of infection is apparent and evidence formostifnotallpro-inflammatory mediators.Glucocorticoids showsbody-wide,systemicinflammation.Systemicinflammation alsohavedirectgenomiceffects,calledtransactivation. Theyre- isusuallydefinedbytwoormorecriteria:feverorlowbodytem- quireonlyafewdaysofcellexposuretoglucocorticoids.Indeed, perature,anincreaseordecreaseinwhitebloodcells,anincreasein conformational changes (i.e. dimerization of the G-GRα com- heartrateandrapidbreathing(ACCP/SCCM1992;Bone1991). plex)areneededbeforethiscomplexcanmigratetothenucleus Severesepsisisdiagnosedwhensepsisisassociatedwithorganfail- tointeractwithglucocorticoid-responsiveelements,thatis,parts ureorhypoperfusion.Septicshockisreportedwhenseveresep- ofgenesencodingforregulatorsofterminationofinflammation. sis is combined with a fallin systemicblood pressure thatdoes Then,keyanti-inflammatoryfactorsareup-regulated,leadingto not improve even when healthcare staff give intravenous fluids. phagocytosis,chemokinesisandanti-oxidativeprocesses.Thenet Discussionamongthescientificcommunityrevealstheneedfora effectofglucocorticoidsinvolvesreprogrammingratherthanin- morepragmaticdefinition,suchassepsiscorrespondingtoinfec- hibiting immune cellfunction (Erschen2007). Glucocorticoids tioncombinedwithorganfailureorhypoperfusion,orsepticshock induce specific activated anti-inflammatory monocyte subtypes correspondingtovasopressor-dependentsepsis(Vincent2013).A thatmigratequicklytoinflamedtissues(Varga2008).Theypro- taskforcesetupbytheSocietyofCriticalCareMedicineandthe longedsurvivalofthissubtypeofmonocytesviaA3adenosinere- EuropeanSocietyofIntensiveCareMedicinerecentlyintroduced ceptor-triggeredanti-apoptoticeffects(Barczyk2010).Obviously, anewdefinitionofsepsisandsepticshock(Singer2015).Sepsisis thesemolecularmechanismsofactionofglucocorticoidsareap- seenwhenaninfectioniscomplicatedbyorganfailures,asdefined propriate for counteracting the uncontrolled inflammation that by a sequential organ failure assessment (SOFA)score (Vincent maycharacterizesepsis. 1996)oftwoorhigher.Septicshockisnotedwheninfectionis complicatedbyhypotensionthatrequiresuseofvasopressorther- apywhilelactatelevelsareincreasedtoabove2mmol/L.Current Howtheinterventionmightwork incidenceofsepsisinindustrializedcountriesrangesfrom50to Researchers have explored the biological mechanisms of sepsis 100casesper100,000 population, withshort-termmortalityof 20%to50%(Annane2003;Finfer2004;Martin2003;Padkin to explore potential interventions. Corticosteroids have been a 2003;TheEPISPESISGroup2004).Peopleusuallydiefromhy- topicofparticularfocusbecauseoftheirinfluenceontheimmune potensionorfromprogressivemultipleorganfailure(Angus2013; response. In sepsis, the hypothalamic-pituitary gland hormonal Annane2005;Parrillo1993). pathway totheadrenal glands stimulatescorticosteroidproduc- tion(Chrousos1995;Cooper2003).Thesehormonesaffectin- flammation through production of white blood cells, cytokines (proteinsthatinfluence theimmune response)andnitricoxide. Descriptionoftheintervention In sepsis, cytokines may suppress adrenocorticotropin hormone Corticosteroids include the natural steroid hormones produced synthesis(Polito2011;Sharshar2003)andthecortisolresponse byadrenocorticalcellsandabroadvarietyofsyntheticanalogues. toexogenousadrenocorticotropinhormone(Hotta1986;Jaattela Thesesubstanceshavevariouseffectsthatmaybegrosslyclassified 1991).Likewise,sepsismaybeassociatedwithalterationsinscav- intoglucocorticoidandmineralocorticoideffects.Glucocorticoid engerreceptorB1-mediatedcholesteroldelivery(Cai2008).This effectsincludemainlyregulationofcarbohydrates,lipidsandpro- causes poor adrenal activity in almost half of patients (Annane teinsmetabolism,aswellasregulationofinflammation.Mineralo- 2000; Lipiner 2007; Marik 2008; Rothwell 1991) and possible corticoideffectsincludemainlyregulationofelectrolytesandwa- resistanceofbodytissuestocorticosteroids(Meduri1998a)due termetabolism.Atmolecularlevels,glucocorticoidshavenon-ge- tofewercorticosteroidreceptorsorreceptorswithloweraffinity nomicandgenomiceffects.Rapid(withinminutes)non-genomic (Barnes1995;Huang1987;Molijn1995).Alterationincorticos- effectsofglucocorticoidsincludeadecreaseinplateletaggregation, teroidreceptornumbersandinbindingcapacitymayberelatedat incelladhesionandinintracellularphosphotyrosinekinases,and leastinparttonitricoxide(Duma2004;Galigniana1999).Recent theyincludeanincreaseinannexin1externalization(Lowenberg workssuggestthatimmunecells-notsteroid-secretingcells-are 2005). These effects may result from interaction of glucocorti- keyregulatorsoftheinteractionbetweentheimmunesytemand coidswithspecificmembranesites(Norman2004).Glucocorti- theadrenals(Kanczkowski2013).Inaddition,acuteillnesssuch coidshaveindirectgenomiceffects,calledtransrepression(Rhen assepsismaybeassociatedwithdecreasedcortisolclearancefrom 2005).Theseoccurwithinafewhoursfollowingexposureofcells plasma(Boonen2013;Melby1958),likelyresultingfromaltered toglucocorticoids.Theyresultfromphysicalinteractionbetween hepatic and renal inactivation of cortisol (Boonen 2013), Early Corticosteroidsfortreatingsepsis(Review) 7 Copyright©2018TheCochraneCollaboration.PublishedbyJohnWiley&Sons,Ltd. studiesshowedthatapharmacologicaldoseofcorticosteroidspro- 2008).Inonestudy,thecombinationofhydrocortisoneandflu- longedsurvivalamonganimalswithsepsis(Fabian1982).More drocortisonegivenatlowdosesforoneweekwasassociatedwith recentstudiesinrodentshavedemonstratedthatlowerdosesof reduceddurationofshockandoforganfailureandreducedmor- corticosteroids, for example, 0.1 mg/kg of dexamethasone, im- talityamongpatientswithsepticshock,andabluntedresponseto provedhaemodynamicandorganfunction,favourablymodulated corticotrophinwasreported(Annane2002).Inthesecondtrial, theinflammatoryresponseandprolongedsurvival(diVillaBianca hydrocortisonewasgivenaloneforfivedaysandwastaperedoff 2003;Heller2003;Tsao2004;Vachharajani2006).Protectiveef- oversixadditional days(Sprung2008).Thistrialfoundsignifi- fectsof theseglucocorticoids against sepsis may be mediatedin cantreductionindurationandintensityofshockandorganfailure partbytheendothelialglucocorticoidreceptor(Goodwin2013). showednosurvivalbenefit.Inadditiontodifferencesintreatment In healthyvolunteers challenged with endotoxin, a low dose of modalities,majordiscrepanciesbetweenthesetrials(Annane2002 corticosteroids,forexample,10mgofprednisolone,blockedthe vsSprung2008)includeddifferencesinroutinepracticesatthe releaseofpro-inflammatorycytokines,preventedendothelialcell timethesestudieswereconducted (novsbroaduse ofcorticos- andneutrophilactivationandinhibitedtheacutephaseresponse teroidsinsepsis),differencesinseverityofillness(highvslowbase- without altering coagulation and fibrinolysis balance (de Kruif lineriskofdeath)anddifferencesinpopulations(mostlymedical 2007).Studiesinpatientswithsepticshockshowedthatashort intensivecareunit(ICU)patientswithlunginfectionvsmostly courseofcorticosteroidsmayresultinareboundinthesystemic surgicalICUpatientswithabdominalinfection).Thereafter,in- inflammatoryresponse(Briegel1994;Keh2003).Inaddition,itis ternationalguidelineshavesuggestedthatcorticosteroidsshould nowrecognizedthatincreasedpro-inflammatorycytokinerelease beusedonlyinpatientswithsepticshockwhoarepoorlyrespon- can be sustained for longer than a week in patients with sepsis sivetofluidreplacementandvasopressortherapy(Dellinger2008; (Kellum2007). Likewise, timing of initiation of corticosteroids Dellinger2013). maybeanimportantfactorinresponsetotreatment.Indeed,in Wethereforeaimtosystematicallyreviewtheeffectsofcorticos- observationalstudies,short-termmortalityincreasedwithdelayed teroidsinpatientswithsepsis. initiationofhydrocortisone(Katsenos2014;Park2012).Forthese reasons,wewouldanticipatethatcorticosteroidtreatmentisben- eficialforpatientswithsepsis,andthatdifferencesindose,timing ordurationofsteroidtreatmentmaydifferentiallyaffectpatient OBJECTIVES responsetotreatment. Toexaminetheeffectsofcorticosteroidsondeathatonemonth inpatientswithsepsis,andtoexaminewhetherdoseandduration Whyitisimportanttodothisreview ofcorticosteroidsinfluencepatientresponsetothistreatment. Initially, researchers used high doses of corticosteroids, usually givenasasinglebolus,inanattempttoblockpotentialburstsin METHODS pro-inflammatory cytokines. Two systematic reviews and meta- analysesoftrialsofcorticosteroidsinsepsisorinsepticshockin- cluded10(Lefering1995)andnine(Cronin1995)randomized controlledtrials,respectively.Thesesystematicreviewsshowedno Criteriaforconsideringstudiesforthisreview significantdifferenceinrelativeriskofdeath,andnosignificant increaseinriskofgastrointestinalbleedingorsuperinfectionasso- ciatedwithcorticosteroids. Typesofstudies Subsequently, most clinicians will not recommend use of high Weincludedrandomizedcontrolledtrials(RCTs)withorwithout doses of corticosteroids in sepsis. However, this review covered blinding. aperiodfrom1966to1993anddidnotexcludepotentialben- efits of a lower dose (≤ 300 mg of hydrocortisone or equiva- lent per day) and a longer duration at full dose (≥ three days) Typesofparticipants oftreatment,asinvestigatedinrandomizedcontrolledtrialsover Weincludedchildrenandadultswith sepsisdefinedby thefol- thepasttwodecades(Annane2002;Arabi2011;Bollaert1998; lowingcriteria(ACCP/SCCM1992;Vincent2013). Briegel1999; Chawla1999;Cicarelli2007;Confalonieri 2005; • DocumentedinfectiondefinedascultureorGramstainof Gordon2014;Hu2009;Huh2007;Keh2003;Liu2012;Meduri blood,sputum,urineornormallysterilebodyfluidthatis 2007; Meijvis 2011; Mikami 2007; Oppert 2005; Rezk 2013; positiveforapathogenicmicro-organism;orafocusofinfection Rinaldi 2006;Sabry 2011;Snijders2010; Tandan 2005;Torres identifiedbyvisualinspection(e.g.rupturedbowelwiththe 2015;Valoor2009;Yildiz2002;Yildiz2011).Amongthesetrials, presenceoffreeairorbowelcontentsintheabdomenfoundat thetwolargestyieldeddifferentfindings(Annane2002;Sprung thetimeofsurgery;woundwithpurulentdrainage);and Corticosteroidsfortreatingsepsis(Review) 8 Copyright©2018TheCochraneCollaboration.PublishedbyJohnWiley&Sons,Ltd. • Atleasttwosymptomsofasystemicinflammatoryresponse daymortality,unlesswecouldobtainactual28-daymortalityrates syndrome,suchasfever(bodytemperature>38°C)or fromstudyauthors. hypothermia(<36°C),tachycardia(>90beatsperminute), tachypnoea(>20breathsperminute)orhyperventilation Secondaryoutcomes (arterialcarbondioxidetension(PaCO )<32mmHg)and 2 • ICUmortality. abnormalwhitebloodcellcount(>12,000cells/mLor<4000 • Hospitalmortality. cells/mL)ormorethan10%immaturebandofneutrophils;and • Numberofparticipantswithshockreversal(asdefinedby • Atleastonesignoforgandysfunction,thatis,metabolic stablehaemodynamicstatus≥24hoursafterwithdrawalof acidosis,arterialhypoxaemia(arterialoxygentension[PaO ]: 2 vasopressortherapy)atdaysevenandatday28. fractionalinspiredoxygen[FiO ]<250mmHg),oliguria(<30 2 • Numberoforgansaffectedandseverityoforgan mL/hfor≥threehours),coagulopathyorencephalopathy;and dysfunctionatdayseven,asmeasuredbythesequentialorgan • Septicshockdefinedbyacombinationofthesecriteriaand failureassessment(SOFA)score(Vincent1996). thepresenceofhypotension(persistingsystolicarterialpressure< • LengthofstayintheICU(forallparticipantsandfor 90mmHg)thatisrefractorytofluidresuscitationandrequires survivorsonly). vasopressorsupport,thatis,morethan5µg/kgofbodyweight • Lengthofhospitalstay(forallparticipantsandforsurvivors perminuteofdopamineoranydoseofepinephrineor only). norepinephrine. • Adverseevents(i.e.gastrointestinalbleedingand Weincludeddatafromtrialsofacuterespiratorydistresssyndrome superinfectionoranyotheradverseeffectsorcomplicationsof (ARDS)whenseparate datawereavailablefor participants with corticosteroidtreatment). sepsis,orwhencontactwithstudyauthorsresultedinprovision ofthedata. Searchmethodsforidentificationofstudies Typesofinterventions We attempted to identify all relevant studies regardless of lan- guageorpublicationstatus(published,unpublished,inpress,in progress). Intervention Systemic treatment with any type of corticosteroid preparation Electronicsearches (e.g.cortisone,hydrocortisone,methylprednisolone,betametha- sone,dexamethasone). Weoriginally searchedtheCochrane Infectious DiseasesGroup Low-dosecorticosteroidwasdefinedbyatotaldoseperdayof400 TrialsRegisterforrelevanttrials(toAugust2003)usingthesearch mgorlessofhydrocortisone(orequivalent);otherwisethedose terms’sepsis’and’septicshock’.Fulldetailsonthemethodsofthe ofcorticosteroidwouldbeconsideredashigh.Alongcoursefor Cochrane Infectious Diseases Group and of the journals hand- theinterventionwasdefinedbyafull-dosetreatmentdurationof searchedarepublishedinTheCochraneLibraryinthesectionon threeormoredays;otherwisetreatmentwasconsideredasashort CochraneReviewGroups. course. Inthisupdatedversion,wesearchedtheCochraneCentralRegister ofControlledTrials(CENTRAL;2014Issue10)usingthesearch terms’sepsis’,’septicshock’,’steroids’and’corticosteroids’(forthe Control detailedsearchstrategy,seeAppendix1). Standardtherapy(whichmayhaveincludedantibiotics,fluidre- Wealsosearched(uptoOctober2014)MEDLINE,EMBASEand placement,inotropicorvasopressortherapy,mechanicalventila- LatinAmericanCaribbeanHealthSciencesLiterature(LILACS) tionorrenalreplacementtherapy)orplacebo. using the topic search terms in combination with the search strategy for identifying trials developed by The Cochrane Col- Typesofoutcomemeasures laboration (Higgins 2011). (For detailed search strategies, see Appendix2(MEDLINE),Appendix3(EMBASE)andAppendix 4(LILACS)). Primaryoutcomes • 28-Dayall-causemortality. Searchingotherresources Indeed,thiswastheprimaryoutcomemeasureinmostoftheRCTs Wecheckedthereferencelistsofalltrialsidentifiedbythesemeth- on sepsis conducted since 1992 (Annane 2009b). Most studies ods, and wecontacted study authorstorequest additional pub- performed before 1992 looked at 14-day or hospital mortality lishedorunpublisheddata.Wealsosearchedtheproceedingsof rates.Weusedthesedatatocomputethepooledanalysison28- annual meetings of major critical care medicine symposia, that Corticosteroidsfortreatingsepsis(Review) 9 Copyright©2018TheCochraneCollaboration.PublishedbyJohnWiley&Sons,Ltd. is, Society of Critical Care Medicine, American Thoracic Soci- many (and thereasons why)participants werelosttofollow-up ety,InternationalSymposiumonIntensiveCareandEmergency orwerenotincludedinanalyses.Whenavailable,wecompared Medicine, AmericanCollegeof ChestPhysicians and European outcomesreportedintrialprotocolsversusactualresultsreported, SocietyofIntensiveCareMedicine(1998to2014). toidentifypotentialselectivereportingbias.Weresolveddisagree- Finally, we searched for ongoing RCTs (October 2014) in the mentsbetweenthefivereviewauthorsbydiscussionwiththesixth metaRegister of Controlled Trials using the search terms ’sep- reviewauthor(EB)untilconsensuswasreached.Onereviewau- ticshock’,’sepsis’,steroids’,’corticosteroids’,’adrenalcortexhor- thor(DA)contactedstudyauthorsforclarification,whenneces- mones’ and ’glucocorticoids’ (www.controlled-trials.com/mrct/ sary. active). Measuresoftreatmenteffect • Weperformedintention-to-treat(ITT)analyses.We Datacollectionandanalysis performedallstatisticalcalculationsusingRevMan5orSTATA/ ICversion10.1(StataCorp,CollegeStation,Texas)as Selectionofstudies appropriate. • Wecalculatedaweightedtreatmenteffectacrosstrials.We Allreviewauthorscheckedthetitlesandabstractsidentifieddur- expressedresultsasriskratios(RRs)with95%confidence ingthesearch.Allreviewauthorsexaminedinfullanytrialthat intervals(CIs)fordichotomousoutcomes,andasmean potentiallymettheinclusioncriteria.Fivereviewauthors(Djillali differences(MDs,95%CIs)forcontinuousoutcomes. Annane, Pierre Edouard Bollaert,JosefBriegel, Didier Kehand YizhakKupfer)evaluatedalltrials,exceptthoseinwhichtheyhad participated.Wedecidedwhichtrialsfittedtheinclusioncriteria Unitofanalysisissues and graded their methodological quality. We resolved disagree- Inthisreview,weuseddatafromtrialsinwhichtheunitofran- mentsbetweenthefivereviewauthorsbydiscussionwiththesixth domizationwasanindividual,andinwhichparallelgroupswere reviewauthor(EricBellissant)untilconsensuswasreached.One designed.Foreventsthatmayoccurrepeatedly,suchasreceiving reviewauthor(DjillaliAnnane)contactedstudyauthorsforclari- vasopressortherapy,weusedonlythefirstoccurrenceoftheevent. fication,whennecessary. Dealingwithmissingdata Dataextractionandmanagement Wesystematicallytriedtocontactprimaryauthorsoforiginaltrials Onereviewauthor(DA)drewupastandarddataextractionform, toobtainmissinginformationandunpublisheddata. andfourotherreviewauthors(PEB,JB,DK,YK)amendedand validatedthedesignoftheformbeforedataabstraction.Fourre- viewauthors(DA,PEB,JB,DK)independentlyextracteddata, Assessmentofheterogeneity exceptthosefromtrialsinwhichtheyhadparticipated.Onere- We considered that evidence for significant heterogeneity was view author (DA) systematically contacted the authors of trials presentwhenI2>30%. torequestmissingdatawhenpossible.Onereviewauthor(DA) entered(DAsecretaryindependentlyreenteredalldatatoachieve Assessmentofreportingbiases adouble entry)thedatainto thecomputer,and fivereviewau- thors(EB,PEB,JB,DK,YK)checkedtheaccuracyofdataentered Wesoughtevidenceofpublicationbiasbyusingthefunnelplot againsttheoriginalarticles. method. WeusedSTATA/ICversion 10.1 (StataCorp, College Station,Texas)toprepareacontour-enhancedfunnelplot(Peters 2008). This graphical analysis used the log of the RR and the Assessmentofriskofbiasinincludedstudies standard error of the RR. We plotted contours illustrating the Weassessedriskofbiaswithinindividualtrialsasrecommended statistical significance of study effect estimates by using a two- bytheCochraneHandbookforSystematicReviewsofInterventions tailedtest. (Higgins2011).Weconsideredthefollowingdomains:selection bias,performancebias,detectionbias,attritionbias,reportingbias Datasynthesis andanyotherbias.Wejudgedselectionbiasonthebasisofhow therandomsequencewasgeneratedandhowallocationwascon- Weconsidered methodsbasedon therandom-effectsmodel for cealed.Wejudgedperformancebiasanddetectionbiasontheba- all analyses, except when we found no evidence for significant sisofwhowasblindedandhow,amongparticipants,care-givers, heterogeneityintheresults.Indeed,wesuspectedthatwewould pharmacists,datacollectors,outcomeassessorsanddataanalysts observeheterogeneityacrossstudies,astheywereconductedover (Devereaux2001).Injudgingattrition bias,weconsideredhow a wide period of time (almost half a century between first and Corticosteroidsfortreatingsepsis(Review) 10 Copyright©2018TheCochraneCollaboration.PublishedbyJohnWiley&Sons,Ltd."
  },
  "meta": {
    "findit_url": "http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC6494587&blobtype=pdf"
  }
}